{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T03:52:24Z","timestamp":1773460344997,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,4,23]],"date-time":"2014-04-23T00:00:00Z","timestamp":1398211200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1007\/s40261-014-0193-2","type":"journal-article","created":{"date-parts":[[2014,4,22]],"date-time":"2014-04-22T12:57:15Z","timestamp":1398171435000},"page":"441-448","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacokinetic and Exposure\u2013Response Analyses of Leuprolide Following Administration of Leuprolide Acetate 3-Month Depot Formulations to Children with Central Precocious Puberty"],"prefix":"10.1007","volume":"34","author":[{"given":"Nael M.","family":"Mostafa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balakrishna","family":"Hosmane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lois M.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristof","family":"Chwalisz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Lin","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajendra S.","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,23]]},"reference":[{"issue":"7","key":"193_CR1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2165\/00003088-200241070-00003","volume":"41","author":"P Periti","year":"2002","unstructured":"Periti P, Mazzei T, Mini E. Clinical pharmacokinetics of depot leuprorelin. Clin Pharmacokinet. 2002;41(7):485\u2013504.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"193_CR2","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1542\/peds.2008-1783","volume":"123","author":"JC Carel","year":"2009","unstructured":"Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert, ESPE-LWPE S GnRH Analogs Consensus Conference Group, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009;123(4):752\u201362.","journal-title":"Pediatrics"},{"key":"193_CR3","unstructured":"LUPRON DEPOT-PED\u00ae [package insert]. North Chicago, IL: Abbott Laboratories."},{"issue":"1","key":"193_CR4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1687-9856-2011-7","volume":"2011","author":"PA Lee","year":"2011","unstructured":"Lee PA, Neely EK, Fuqua J, Yang D, Larsen L, Mattia-Goldberg C, Chwalisz K. Efficacy of leuprolide acetate 1-month depot for central precocious puberty (CPP): growth outcomes during a prospective, longitudinal study. Int J Pediatr Endocrinol. 2011;2011(1):7.","journal-title":"Int J Pediatr Endocrinol"},{"issue":"5","key":"193_CR5","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1210\/jc.2011-2704","volume":"97","author":"PA Lee","year":"2012","unstructured":"Lee PA, Klein K, Mauras N, Neely EK, Bloch CA, Larsen L, Mattia-Goldberg C, Chwalisz K. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. J Clin Endocrinol Metab. 2012;97(5):1572\u201380.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"193_CR6","first-page":"851","volume":"76","author":"LR Garibaldi","year":"1993","unstructured":"Garibaldi LR, Aceto T Jr, Weber C, Pang S. The relationship between luteinizing hormone and estradiol secretion in female precocious puberty: evaluation by sensitive gonadotropin assays and the leuprolide stimulation test. J Clin Endocrinol Metab. 1993;76(4):851\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"193_CR7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1530\/eje.1.02056","volume":"154","author":"JC Carel","year":"2006","unstructured":"Carel JC, Blumberg J, Seymour C, Adamsbaum C, Lahlou N. Three-month sustained-release triptorelin (11.25\u00a0mg) in the treatment of central precocious puberty. Eur J Endocrinol. 2006;154(1):119\u201324.","journal-title":"Eur J Endocrinol"},{"issue":"22","key":"193_CR8","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1056\/NEJMcp0800459","volume":"358","author":"JC Carel","year":"2008","unstructured":"Carel JC, L\u00e9ger J. Clinical practice. Precocious puberty. N Engl J Med. 2008;358(22):2366\u201377.","journal-title":"N Engl J Med"},{"issue":"2","key":"193_CR9","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/jps.2600750211","volume":"75","author":"LT Sennello","year":"1986","unstructured":"Sennello LT, Finley RA, Chu SY, et al. Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration. J Pharm Sci. 1986;75(2):158\u201360.","journal-title":"J Pharm Sci"},{"issue":"Suppl 2","key":"193_CR10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000056547","volume":"60","author":"D Jocham","year":"1998","unstructured":"Jocham D. Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: long-term follow-up results. Urol Int. 1998;60(Suppl 2):18\u201324 discussion 35.","journal-title":"Urol Int"},{"key":"193_CR11","author":"NM Mostafa","year":"2014","unstructured":"Mostafa NM, Chwalisz K, Larsen L, Mattia-Goldberg C, Spitz A, Pradhan RS. Evaluation of the pharmacokinetics and pharmacodynamics of two leuprolide acetate 45\u00a0mg 6-month depot formulations in patients with prostate cancer. Clin Pharmacol Drug Dev. 2014;. doi: 10.1002\/cpdd.112 .","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"9","key":"193_CR12","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1210\/jc.2001-020243","volume":"87","author":"JC Carel","year":"2002","unstructured":"Carel JC, Lahlou N, et al. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25\u00a0mg). J Clin Endocrinol Metab. 2002;87(9):4111\u20136.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-014-0193-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-014-0193-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-014-0193-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T19:28:52Z","timestamp":1559503732000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-014-0193-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,23]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["193"],"URL":"https:\/\/doi.org\/10.1007\/s40261-014-0193-2","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,23]]}}}